Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers

European Journal of Clinical Investigation

Volumn 29, Issue 7, 1999, Pages 637-642

  Gonzalez C ^a,b   Martin T ^a   Cacho, J ^a   Brenas M T ^a   Arroyo, T ^a   Garcia Berrocal B ^a   Navajo, J A ^a   Gonzalez Buitrago J M ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Alzheimer's disease; Apolipoprotein E; Copper; Insulin; Lipids; Zinc

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN E4; CHOLESTEROL; COPPER; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL; ZINC;

AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ZINC BLOOD LEVEL;

EID: 0033062186     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00471.x     Document Type: Article

References (39)

1. 1 Blacker D, Tanzi RE. The genetics of Alzheimer's disease. current status and future prospects. Arch Neurol 1998; 55: 294-6.
2. 2 Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet 1998; 19: 357-60.
3. 3 American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statements on use of apolipoprotein E testing for Alzheimer Disease. JAMA 1995; 274: 1627-9.
4. 4 Jordan BD, Relkin NR, Ravdin LS, Jacobs AR, Bennet A, Gandy S. Apolipoprotein E epsilon 4 associated with chronic traumatic brain injury in Boxing. JAMA 1997; 278: 136-40.
5. 5 Bush AI, Pettingel WH, Multhaup G, et al. Rapid induction of Alzheimer A-beta amiloid formation by zinc. Science 1994; 265: 1464-7.
6. 6 Aschner M, Cherian MG, Klaasen CD, Palmiter RD, Erickson JC, Bush AI. Metallothioneins in brain-the role in physiology and pathology. Toxicol Appl Pharmacol 1997; 142: 229-42.
7. 7 Mok SS, Evin G, Smith AI, Beyreuther K, Masters CL, Small DH. A novel metalloprotease in rat brain cleaves the amyloid precursor protein of Alzheimer's disease generating amyloidogenic fragments. Biochemistry 1997; 36: 156-63.
8. 8 Deibel MA, Ehman WD, Markesbery WR. Copper, iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996; 143: 137-42.
9. 9 Stamler JS. A radical vascular connection. Nature 1996; 380: 108-11.
10. 10 Pall HS. Raised cerebrospinal-fluid copper concentrations in Parkinson's disease. Lancet 1987; 2: 238.
11. 11 Vance DE, Ehman WD, Markesbery WR. A search for longitudinal variations in trace element levels in nails of Alzheimer's disease patients. Biol Trace Elem Res 1990; 26-27: 461-70.
12. 12 Licastro F, Davis LJ, Mocchegiani E, Fabris N. Impaired peripheral zinc metabolism in patients with senile dementia of probable Alzheimer's type as shown by low plasma concentrations of thymulin. Biol Trace Elem Res 1996; 51: 55-62.
13. 13 Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer Disease. JAMA 1995; 273: 942-7.
14. 14 Reiman EM, Caselli RJ, Yun LS. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-8.
15. 15 Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer Disease and differing apolipoprotein E genotypes. Arch Neurol 1997; 54: 273-7.
16. 16 Razay G, Wicock GK. Hyperinsulinemia and Alzheimer's disease. Age Ageing 1994; 23: 396-9.
17. 17 Meneilly Gs Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc 1993; 41: 710-4.
18. 18 Dart A, Sherrard B, Simpson H. Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Atherosclerosis 1997; 130: 161-70.
19. 19 Siest G, Pillot T, Régis-Bailly A, et al. An important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-86.
20. 20 Cumming AM, Robertson FW. Polymorphism at the apolipoprotein E locus in relation to risk of coronary disease. Clin Genet 1984; 25: 310-3.
21. 21 Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol and coronary artery disease. Clin Chem 1986; 32: 778-81.
22. 22 Kussi T, Nieinen MS, Ehnholm C, et al. Apolipoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically defined coronary patients. Arteriosclerosis 1989; 9: 237-41.
23. 23 Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995; 45: 1092-6.
24. 24 McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34: 939-44.
25. 25 Arnaud J, Bellenger J, Bienvenu F, Chappuis F, Favier A. Recommended method for assaying serum zinc with flame atomic absorption. Ann Biol Clin 1986; 44: 77-87.
26. 26 Post SG, Withehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease. JAMA 1907; 277: 832-6.
27. 27 Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338: 506-11.
28. 28 Pedro-Botet J, Rubiés-Prat J. Apolipoproteína F y enfermedad. Med Clin 1997; 109: 216-8.
29. 29 Lahoz C, Ordovás JM. Apo E: lípidos plasmáticos, cardiopatcía isquémica y enfermedad de Alzheimer. Med Clin 1997; 109: 31-6.
30. 30 Cacho J, Breñas T, González C, et al. Genotipo y fenotipo de la apolipoproteina E en enfermos de Alzheimer en Castilla y León. Neurología 1997; 12: 384-8.
31. 31 Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between Apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997; 278: 1349-56.
32. 32 Cotton P. Constellations of risks and processes seen in search for Alzheimer's clues. JAMA 1994; 271: 89-91.
33. 33 Cupples LA, Heeren T, Schatzkin A, Colton T. Multiple testing of hypothesis in comparing two groups. Ann Intern Med 1984; 100: 122-9.
34. 34 Kilander L, Boberg M, Lithell H. Peripheral glucose metabolism and insulin sensitivity in Alzheimer's disease. Acta Neurol Scand 1993; 87: 294-8.
35. 35 Berger GM, Naidoo J, Gounden N, Gouws E. Marked hyperinsulinemia in postmenopausal healthy Indian (Asian) women. Diabet Med 1995, 12: 788-95.
36. 36 Srinivasan SR, Ehnholm C, Wattigney WA, Bao W, Berenson GS. The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis 1996; 123: 33-42.
37. 37 Valdez R, Howard BV, Stern MP, Haffner SM. Apolipoprotein E polymorphism and insulin levels in a biethnic population. Diabetes Care 1995; 18: 992-1000.
38. 38 Kamboh MI, Aston CE, Hamman RF. The relationship of ApoE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 1995; 112: 145-59.
39. 39 Haviland MB, Lussier-Cacan S, Davignon J, Sing CF. Impact of apolipoprotein E genotype variation on means, variances and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Am J Med Genet 1995; 58: 315-31.